Background - β-Blocker efficacy in long-QT syndrome type 1 is good but variably reported, and the causes of cardiac events despite β-blocker therapy have not been ascertained. Methods and Results - This was a retrospective study of the details surrounding cardiac events in 216 genotyped long-QT syndrome type 1 patients treated with β-blocker and followed up for a median time of 10 years. Before β-blocker, cardiac events occurred in 157 patients (73%) at a median age of 9 years, with cardiac arrest (CA) in 26 (12%). QT-prolonging drugs were used by 17 patients; 9 of 17 (53%) had CA compared with 17 of 199 nonusers (8.5%; odds ratio, 12.0; 95% confidence interval, 4.1 to 35.3; P<0.001). After β-blocker, 75% were asymptomatic, and cardiac events were significantly reduced (P<0.001), with a median event count (quartile 1 to 3) per person of 0 (0 to 1). Twelve patients (5.5%) suffered CA/sudden death, but 11 of 12 (92%) were noncompliant (n=8), were on a QT-prolonging drug (n=2), or both (n=1) at the time of the event. The risk for CA/sudden death in compliant patients not taking QT-prolonging drugs was dramatically less compared with noncompliant patients on QT-prolonging drugs (odds ratio, 0.03; 95% confidence interval, 0.003 to 0.22; P=0.001). None of the 26 patients with CA before β-blocker had CA/sudden death on β-blockers. Conclusions - β-Blockers are extremely effective in long-QT syndrome type 1 and should be administered at diagnosis and ideally before the preteen years. β-Blocker noncompliance and use of QT-prolonging drug are responsible for almost all life-threatening "β-blocker failures." β-Blockers are appropriate therapy for asymptomatic patients and those who have never had a CA or β-blocker therapy. Routine implantation of cardiac defibrillators in such patients does not appear justified

Vincent, G., Schwartz, P., Denjoy, I., Swan, H., Bithell, C., Spazzolini, C., et al. (2009). High efficacy of beta-blockers in Long QT Syndrome type 1: contribution of non-compliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. CIRCULATION, 119(2), 215-221 [10.1161/CIRCULATIONAHA.108.772533].

High efficacy of beta-blockers in Long QT Syndrome type 1: contribution of non-compliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”.

Crotti L;
2009

Abstract

Background - β-Blocker efficacy in long-QT syndrome type 1 is good but variably reported, and the causes of cardiac events despite β-blocker therapy have not been ascertained. Methods and Results - This was a retrospective study of the details surrounding cardiac events in 216 genotyped long-QT syndrome type 1 patients treated with β-blocker and followed up for a median time of 10 years. Before β-blocker, cardiac events occurred in 157 patients (73%) at a median age of 9 years, with cardiac arrest (CA) in 26 (12%). QT-prolonging drugs were used by 17 patients; 9 of 17 (53%) had CA compared with 17 of 199 nonusers (8.5%; odds ratio, 12.0; 95% confidence interval, 4.1 to 35.3; P<0.001). After β-blocker, 75% were asymptomatic, and cardiac events were significantly reduced (P<0.001), with a median event count (quartile 1 to 3) per person of 0 (0 to 1). Twelve patients (5.5%) suffered CA/sudden death, but 11 of 12 (92%) were noncompliant (n=8), were on a QT-prolonging drug (n=2), or both (n=1) at the time of the event. The risk for CA/sudden death in compliant patients not taking QT-prolonging drugs was dramatically less compared with noncompliant patients on QT-prolonging drugs (odds ratio, 0.03; 95% confidence interval, 0.003 to 0.22; P=0.001). None of the 26 patients with CA before β-blocker had CA/sudden death on β-blockers. Conclusions - β-Blockers are extremely effective in long-QT syndrome type 1 and should be administered at diagnosis and ideally before the preteen years. β-Blocker noncompliance and use of QT-prolonging drug are responsible for almost all life-threatening "β-blocker failures." β-Blockers are appropriate therapy for asymptomatic patients and those who have never had a CA or β-blocker therapy. Routine implantation of cardiac defibrillators in such patients does not appear justified
Articolo in rivista - Articolo scientifico
long qt syndrome, beta-blockers, drugs, long qt syndrome type 1
English
2009
119
2
215
221
reserved
Vincent, G., Schwartz, P., Denjoy, I., Swan, H., Bithell, C., Spazzolini, C., et al. (2009). High efficacy of beta-blockers in Long QT Syndrome type 1: contribution of non-compliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. CIRCULATION, 119(2), 215-221 [10.1161/CIRCULATIONAHA.108.772533].
File in questo prodotto:
File Dimensione Formato  
Vincent-BetaBlockers Circulation09.pdf

Solo gestori archivio

Dimensione 267.81 kB
Formato Adobe PDF
267.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/189643
Citazioni
  • Scopus 258
  • ???jsp.display-item.citation.isi??? 206
Social impact